JUN 19, 2018 10:34 PM PDT

Triple Negative Breast Cancer: Treatment Using Innovative Drug Technology

WRITTEN BY: Nouran Amin

Researchers at Purdue University have created innovative drug technology that may seek to treat one of the most aggressive forms of breast cancer: triple negative breast cancer.

In the United States, triple negative breast cancer (TNBC) occurs in about 10-20% of diagnosed breast cancers. It is also more likely to affect younger people, African Americans, Hispanics, and/or those with a BRCA1 gene mutation.

Currently, the only treatment option for TNBC is chemotherapy. However, chemotherapy is not effective to the degree that it targets cancer cells. Additionally, chemotherapy causes unpleasant side-effects that are often debilitating. Therefore, the need for an innovative targeted therapy that will treat TNBC without adverse effects is stronger than ever.

“TNBC is a very aggressive type of breast cancer with a short survival rate due to lack of available therapeutic drugs used for treatment that will cause minimal side effects,” explains research team leader Meden Isaac-Lam and an associate professor in the Department of Chemistry and Physics at Purdue University Northwest. “There are no known recognized molecular targets for TNBC, making the design of highly specific drugs extremely challenging.”

The Isaac-Lam research team produced drug candidates that are strong at lower concentrations than traditional chemotherapy. This technology utilizes molecules that can be selectively activated by light and absorbed by cancer cells. The therapy is believed to decrease the dosage needed to administer the drug, ultimately reducing side effects and effective in treating TNBC.

“Our proposed solution is to design drugs that target vitamin receptors produced excessively in cancer cells, which compete with normal cells for the vitamins necessary for cellular growth and proliferation,” Isaac-Lam said. “Attaching vitamins on compounds that are light-activated and that are known to be taken up by tumor cells will provide a means of selectively accumulating these synthetic drug-vitamin conjugates in cancer cells more than in healthy cells.”

The technology works by injecting the selected compound into the patient where it accumulates into the cancer cells. These cancer cells are then killed when activated by light.

“This will be an alternative solution to the available therapies that are not selective to the tumor cells causing detrimental effects to the patient’s healthy cells,” Isaac-Lam said. “The technology can be an effective treatment for breast cancer patients who are not responding to the standard conventional therapy.”

Fortunately, these drug candidates that were screened for TNBT may be effective in treatments for other forms of breast cancer.

Sources: Purdue University

About the Author
BS/MS
Nouran is a scientist, educator, and life-long learner with a passion for making science more communicable. When not busy in the lab isolating blood macrophages, she enjoys writing on various STEM topics.
You May Also Like
JUN 06, 2022
Drug Discovery & Development
Express Media Service Q&A with Sheng Li, PhD., FUJIFILM Irvine Scientific
JUN 06, 2022
Express Media Service Q&A with Sheng Li, PhD., FUJIFILM Irvine Scientific
FUJIFILM Irvine Scientific sat down with Sheng Li, PhD, Program Manager, to speak about our rapid service for small-scal ...
JUN 02, 2022
Coronavirus
Loneliness and social isolation may continue to prolong the COVID-19 pandemic
JUN 02, 2022
Loneliness and social isolation may continue to prolong the COVID-19 pandemic
It has been clear for some time that loneliness and social isolation can lead to increased risks for adverse h ...
JUN 26, 2022
Drug Discovery & Development
Vitamin Supplements are a 'Waste of Money' for Healthy Americans
JUN 26, 2022
Vitamin Supplements are a 'Waste of Money' for Healthy Americans
The US Preventive Services Task Force (USPSTF) recommends against using beta carotene or vitamin E supplements to preven ...
JUL 06, 2022
Drug Discovery & Development
The new amphibious origami millirobot can roll, flip, and spin for targeted drug delivery
JUL 06, 2022
The new amphibious origami millirobot can roll, flip, and spin for targeted drug delivery
Drug delivery researchers are constantly exploring ways that can help improve targeted drug delivery. When a drug is ing ...
JUL 12, 2022
Drug Discovery & Development
Nitric Oxide Reduces Hospital Stay of Pregnant Women with COVID-19
JUL 12, 2022
Nitric Oxide Reduces Hospital Stay of Pregnant Women with COVID-19
High-dose nitric oxide can reduce the length of hospital and ICU stay, as well as the need for supplemental oxygen, amon ...
JUL 16, 2022
Drug Discovery & Development
Whole Blood Exchange May Reduce Amyloid Plaques in Alzheimer's
JUL 16, 2022
Whole Blood Exchange May Reduce Amyloid Plaques in Alzheimer's
Whole blood exchange reduces the formation of amyloid beta plaques in mouse models of Alzheimer's disease. The corre ...
Loading Comments...